{"id":"NCT01884311","sponsor":"Bio Products Laboratory","briefTitle":"Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases","officialTitle":"A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-20","primaryCompletion":"2017-05-25","completion":"2017-05-25","firstPosted":"2013-06-24","resultsPosted":"2018-09-12","lastUpdate":"2018-09-12"},"enrollment":38,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Primary Immune Deficiency Disorders","Common Variable Immunodeficiency","X-linked Agammaglobulinaemia","Hyperimmunoglobulin M Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"Subgam","otherNames":["Subgam-VF"]}],"arms":[{"label":"Subgam-VF","type":"EXPERIMENTAL"}],"summary":"The main objective of the study is to determine the pharmacokinetics profile of Subgam-VF. The secondary objectives are to assess the safety of Subgam-VF and refine the dose adjustment coefficient for Subgam-VF needed for subjects switching from prior intravenous immunoglobulin (IGIV) therapy.","primaryOutcome":{"measure":"Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as Log Transformed sAUC0-t Standardized to One Week.","timeFrame":"1 week","effectByArm":[{"arm":"Subgam-VF and Gammaplex 5%","deltaMin":0.98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Infusion Site Erythema","Infusion Site Pain"]}}